To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
CANbridge Pharmaceuticals lands $43m Series E
China and Boston-based CANbridge Pharmaceuticals Inc, a developer of drugs to treat rare diseases and targeted cancers, has raised $43 million in Series E financing.
